<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892019000200006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación del riesgo radiológico en la radiosinoviortesis y el tratamiento mielosupresor de la policitemia vera]]></article-title>
<article-title xml:lang="en"><![CDATA[Radiological risk assessment in radiosynoviorthesis and the myelosupressor treatment of polycythemia vera]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Balbona]]></surname>
<given-names><![CDATA[Zayda Amador]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Valle]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fundora Sarraff]]></surname>
<given-names><![CDATA[Teresa Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Isótopos (CENTIS)  ]]></institution>
<addr-line><![CDATA[Mayabeque ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de La Habana Facultad de Tecnología y Ciencias Aplicadas ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892019000200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892019000200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892019000200006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La aplicación del método de la matriz de riesgo para la evaluación del riesgo radiológico en la medicina permite identificar de manera proactiva debilidades en las etapas del proceso y hacer un plan de acciones de mejora para la seguridad y calidad.  Objetivo:  Evaluar los riesgos radiológicos de la radiosinoviortesis y el tratamiento mielosupresor con Fósforo-32 de la policitemia vera.  Método:  Se utilizó el método de matriz de riesgo y se realizó el análisis y tratamiento de los riesgos radiológicos por medio del código cubano SECURE-MR-FMEA 3.0.  Resultados:  El 17 % del riesgo alto se eliminó con las medidas adicionales adoptadas; predominaron las consecuencias medias para los trabajadores y el público, 30 % y el 14 %, respectivamente. Las defensas más importantes fueron: levantamiento radiológico inicial de las áreas del departamento; revisión independiente del proyecto con las regulaciones de seguridad aplicables; inspección de trabajos de construcción civil y montaje de equipos antes de iniciar la operación del departamento; capacitación de los médicos nucleares en los tratamientos; existencia de protocolos de tratamiento; análisis de lecciones aprendidas de incidentes radiológicos; levantamiento radiológico periódico de las áreas del servicio y procedimiento de emergencia para reducir la dosis en órganos críticos en caso de administración errónea de radiofármacos. Se creó una base de datos de incidentes utilizada como referencia para el modelo utilizado. El factor humano fue la causa mayor de los sucesos radiológicos analizados (88 %).  Conclusiones:  Estos resultados facilitan la toma de decisiones para el mejor desempeño de la radiosinoviortesis y el tratamiento de la policitemia vera con Fósforo-32 en Cuba. Se sugiere elaborar el plan de mejora de la seguridad con especial atención a las operaciones de administración del radiofármaco en ambos casos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The application of risk matrix for ionizing radiation medicine allow identify in proactive way the weakness of the process&#8217; step, which implies in the design of safety and quality improvement plan for this.  Method:  Risk matrix method applied for radiosynoviorthesis and the myelosupressor treatment with Phosphorus-32 of polycythemia vera. The Cuban code SECURE-MR-FMEA 3.0 is used.  Results:  It was eliminated the 17% of the high risk with additional measures, and the medium consequences for workers and public are 30% and 14%, respectively. The most important identified safety measures were the initial radiological monitoring from different nuclear medicine department areas; the project revision based on the applicable safety regulations; a survey of civil construction works and equipment assembly before work began; training of nuclear medicine doctors in related aspects of nuclear medicine treatments; existence of treatment protocols; the analysis of learned lessons from radiological incidents; the periodical radiological monitoring from different services areas and the emergency procedure for the cases of mistake in the radiopharmaceuticals administration. Human factor was the major cause in analyzed radiological events (88 %).  Conclusions:  These results facilitate taking decisions for the best performance of radiosynoviorthesis and the myelosupressor treatment with Phosphorus-32 of polycythemia vera in Cuba. It is recommended to elaborate the safety improvement plan from these and focussing in the radiopharmaceutical administration operations in both cases.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[análisis de riesgo radiológico]]></kwd>
<kwd lng="es"><![CDATA[matriz de riesgo]]></kwd>
<kwd lng="es"><![CDATA[radiosinoviortesis]]></kwd>
<kwd lng="es"><![CDATA[policitemia vera]]></kwd>
<kwd lng="en"><![CDATA[radiological risk analysis]]></kwd>
<kwd lng="en"><![CDATA[risk matrix]]></kwd>
<kwd lng="en"><![CDATA[radiosynoviorthesis]]></kwd>
<kwd lng="en"><![CDATA[polycythemia vera]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buitrago]]></surname>
<given-names><![CDATA[AQ]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Cañón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiosinoviortesis Opción Terapéutica Actual En Sinovitis Crónica]]></article-title>
<source><![CDATA[Rev Médica Sanitas]]></source>
<year>2014</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Querol Giner]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[Opciones Terapéuticas en la Sinovitis en Pacientes Afectos de Hemofilia: Sinoviortesis]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Valencia ]]></publisher-loc>
<publisher-name><![CDATA[Universitat de Valencia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Merchan]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Liddle]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis and treatment options for hemophilic synovitis]]></article-title>
<source><![CDATA[Exp Opinion Orphan Drugs]]></source>
<year>2017</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>173-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atilgan]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[Sadic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Korkmaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiosynovectomy: Current Status and Clinical Utility]]></article-title>
<source><![CDATA[Internat J Health Sci Res]]></source>
<year>2016</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>324-36</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prasanna]]></surname>
<given-names><![CDATA[TY]]></given-names>
</name>
<name>
<surname><![CDATA[Jagdish]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nataraj]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Dhanapathi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Harshith]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-term clinico-radiological outcome of chronic knee synovitis among haemophilia A patients post phosphorus-32 radiosynoviorthesis Single group prospective study]]></article-title>
<source><![CDATA[J Orthop Surg]]></source>
<year>2017</year>
<page-range>25</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz Arencibia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Morales]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterios de calidad de dispersiones radiactivas en radiosinovectomía]]></article-title>
<collab>Izquierdo Pérez J and Morín Zorrilla J</collab>
<source><![CDATA[Nucleus]]></source>
<year>2017</year>
<volume>62</volume>
<page-range>34-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Besses]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Sociedad Española de Hematología y Hemoterapia ]]></publisher-loc>
<publisher-name><![CDATA[Manual de Recomendaciones en Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagalla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Polycythemia Vera Treatment &amp; Management]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delgado Fernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fundora Sarraff]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán Milanés]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fósforo 32. Experiencia de 30 años en la policitemia vera]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2003</year>
<volume>19</volume>
<numero>2-3</numero>
<issue>2-3</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Organismo Internacional de Energía Atómica</collab>
<source><![CDATA[Aplicación de la Matriz de Riesgo a la Radioterapia]]></source>
<year>2012</year>
<publisher-name><![CDATA[IAEA-TECDOC 1685/S]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duménigo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[López Morones]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papadópulos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McDonnell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morales López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Metodología de Matrices de Riesgo. Actualización de la Misma Basada en las Experiencias en su Aplicación]]></source>
<year>2018</year>
<conf-name><![CDATA[ XICongreso Regional de Seguridad Radiológica y Nuclear Congreso Regional IRPA Cultura de Seguridad: un compromiso compartido?]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[La Habana, Cuba ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duménigo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluaciones de seguridad de la práctica de Medicina Nuclear utilizando el método de matrices de riesgo]]></source>
<year>2013</year>
<conf-name><![CDATA[ IXCongreso Latinoamericano del IRPA]]></conf-name>
<conf-loc>Río de Janeiro, Brasil </conf-loc>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amador Balbona]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Valle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del Código SECURE-MR-FMEA para el Análisis de Riesgo Radiológico en Medicina Nuclear Terapéutica Convencional]]></article-title>
<source><![CDATA[J. Health Med Sci]]></source>
<year>2018</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-81</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Ayra]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Albuerne]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Montano]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absorbed dose profiles for 32P, 90Y, 188Re, 177Lu, 51Cr, 153Sm and 169Er radionuclides used in radiosynoviortheses treatment]]></article-title>
<source><![CDATA[Rev Española Med Nucl]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>188-92</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Ministerio de Ciencia, Tecnología y Medio Ambient</collab>
<source><![CDATA[Reglamento sobre Notificación y Autorización de Prácticas y Actividades Asociadas al Empleo de Fuentes de Radiaciones Ionizantes]]></source>
<year>2012</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Centro Nacional de Seguridad Nuclear</collab>
<source><![CDATA[Guía Evaluación de Seguridad de Prácticas y Actividades Asociadas al Empleo de Fuentes de Radiaciones Ionizantes]]></source>
<year>2012</year>
<publisher-loc><![CDATA[La Habana, Cuba ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Oficina Nacional de Normalización.Sistemas de Gestión de la Calidad</collab>
<source><![CDATA[Requisitos, NC ISO 9001,]]></source>
<year>2015</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Cuba]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>International Standard Organization</collab>
<source><![CDATA[ISO 31000: Risk management-Guidelines]]></source>
<year>2018</year>
<edition>Second</edition>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Organismo Internacional de Energía Atómica</collab>
<source><![CDATA[Protección Radiológica y Seguridad de las Fuentes de Radiación. Normas Básicas Internacionales de Seguridad. Requisitos de Seguridad Generales, Parte 3, Nº GSR Part 3,]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Viena ]]></publisher-loc>
<publisher-name><![CDATA[Austria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Centro Nacional de Seguridad Nuclear</collab>
<source><![CDATA[Guía de seguridad para la práctica de Medicina Nuclear]]></source>
<year>2011</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nisar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dosimetry perspectives in radiation synovectomy]]></article-title>
<source><![CDATA[Phys Med]]></source>
<year>2018</year>
<volume>47</volume>
<page-range>64-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Croasdale]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiation Protection Aspects of Radiation Synovectomy Procedures]]></article-title>
<source><![CDATA[RAD Magazine]]></source>
<year>2016</year>
<volume>41</volume>
<numero>483</numero>
<issue>483</issue>
<page-range>15-7</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres Valle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Usuario SECURE-MR-FMEA 30, Programa de análisis de riesgo basado en matriz de riesgo y FMEA]]></source>
<year>2017</year>
<publisher-loc><![CDATA[La Habana, Cuba ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcin Chojnowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Plazinska]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Slawomir Chojnowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Królicki]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta burns following radionuclide synovectomy]]></article-title>
<source><![CDATA[Reumatol]]></source>
<year>2018</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>184-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oztürk]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oztemür]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bulut]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of skin necrosis after radiation synovectomy with yttrium-90 a case report]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2008</year>
<volume>28</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1067-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kampen]]></surname>
<given-names><![CDATA[WU]]></given-names>
</name>
<name>
<surname><![CDATA[Matis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Czech]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Soti]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gratz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Henze]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serious complications after radiosynoviorthesis Survey on frequency and treatment modalities]]></article-title>
<source><![CDATA[Nuklearmedizine]]></source>
<year>2006</year>
<volume>45</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>262-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Colmenero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Ezquerra]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Monfort]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pujol]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistent cutaneous ulcers after Yttrium-90 synovectomy, an unusual complication two case reports and a review of the literature]]></article-title>
<source><![CDATA[Int Wound J]]></source>
<year>2016</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>508-11</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skversky]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mendell]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<source><![CDATA[Polycythemia vera terminating in acute leukemia]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Newberry]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Verstovsek]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New Therapeutic Approaches in Polycythemia Vera]]></article-title>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2015</year>
<volume>15</volume>
<numero>S1</numero>
<issue>S1</issue>
<page-range>S27-33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
